AI Article Synopsis

  • The effectiveness of pazopanib for treating metastatic extraosseous Ewing sarcoma is still uncertain, but a case study shows promising results.
  • A 17-year-old girl with heavily pre-treated metastatic extraosseous Ewing sarcoma experienced disease progression after initial chemotherapy.
  • After starting pazopanib, she showed a significant and lasting response, with improvement lasting over 26 months, indicating it may be a viable treatment option for this condition.

Article Abstract

The clinical efficacy and outcomes of pazopanib treatment for metastatic extraosseous Ewing sarcoma remain unclear. We herein report a case of heavily pre-treated metastatic extraosseous Ewing sarcoma in which pazopanib treatment achieved a significant improvement. A 17-year-old girl was referred to our hospital due to metastatic extraosseous Ewing sarcoma. The initial cytotoxic chemotherapy was temporarily effective, however, her disease eventually progressed, and she was subsequently treated with pazopanib. The recurrent tumor showed a marked response to pazopanib therapy; the therapeutic effect has lasted for more than 26 months. The present case suggests that pazopanib may be a therapeutic option for extraosseous Ewing sarcoma.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191593PMC
http://dx.doi.org/10.2169/internalmedicine.9879-17DOI Listing

Publication Analysis

Top Keywords

extraosseous ewing
20
ewing sarcoma
20
metastatic extraosseous
16
treatment metastatic
8
sarcoma pazopanib
8
pazopanib treatment
8
pazopanib
6
extraosseous
5
ewing
5
sarcoma
5

Similar Publications

Background: The diagnosis of intracranial extraosseous Ewing's sarcoma (EES) poses challenges due to the absence of specific clinical and imaging features prior to surgery. It is crucial to differentiate the tumor from other small round cell malignancies postoperatively.

Observations: A 7-year-old patient was admitted to the authors' hospital due to the in situ recurrence of a posterior fossa tumor more than 1 month after the initial surgery for headache.

View Article and Find Full Text PDF

Intra-neural Ewing sarcoma is an extremely rare tumour and only a few isolated case reports exist in the literature. A 32-year-old South Asian male presented with wrist and finger drops of 3 months duration. Further evaluation with ultrasonography and magnetic resonance imaging revealed a tumour of the radial nerve in the arm.

View Article and Find Full Text PDF

The case report discusses xanthogranulomatous osteomyelitis, a rare inflammatory bone condition that can resemble malignancy on imaging studies. The report details a case of a 42-year-old woman with left leg pain, swelling, and redness lasting 4 months. Imaging revealed a lytic lesion in the left tibia with endosteal erosion, and MRI showed extraosseous soft tissue extension.

View Article and Find Full Text PDF

Primary and Metastatic Pancreatic Ewing Sarcomas: A Case Report and Review of the Literature.

Diagnostics (Basel)

November 2024

Second Department of Pathology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, 15772 Athens, Greece.

Ewing sarcomas are rare tumors arising mainly in the bones and the surrounding soft tissues. Primary extraosseous Ewing sarcomas have also been described in several other organs and locations other than bones, including the pancreas. These tumors have well-defined histological, immunohistochemical, and molecular characteristics.

View Article and Find Full Text PDF

Extraosseous Ewing's sarcoma (EES) is a rare form of Ewing's sarcoma that arises outside the bones in soft-tissue structures. It is thought to result from a genetic abnormality involving the fusion of the EWSR1 gene with various partner genes, most commonly the FLI-1 gene. Common symptoms include pain, swelling, and sometimes a palpable mass at the site of the tumor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!